JHPCY
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Price Chart
Latest Quote
$12.25
+0.00 (+0.00%)
Current Price
| Previous Close | $12.25 |
| Open | $13.00 |
| Day High | $13.00 |
| Day Low | $13.00 |
| Volume | 2 |
Stock Information
Note: Financial values converted from CNY to USD
| Quarterly Dividend / Yield | $0.06 / 0.48% |
| Shares Outstanding | 129.10M |
| Quarterly Dividend Yield | 0.48% |
| Quarterly Dividend | $0.06 |
| Total Debt | $10.21M |
| Cash Equivalents | $5.83B |
| Revenue | $4.93B |
| Net Income | $1.33B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $40.66B |
| P/E Ratio | 31.41 |
| EPS (TTM) | $0.39 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.14B |
| Sales | $4.93B |
| Income | $1.33B |
| Book/sh | $3.03 |
| Cash/sh | $300.87 |
| Employees | 21K |
Financial Ratios
| Quick Ratio | 7.25 |
| Current Ratio | 7.91 |
| Debt/Eq | 0.10 |
| EPS Growth TTM | -15.30% |
Returns & Margins
| ROA | 7.77% |
| ROE | 13.94% |
| Gross Margin | 86.36% |
| Operating Margin | 22.99% |
| Profit Margin | 27.04% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/S | 1.24 |
| P/B | 4.04 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $12.34 |
| SMA50 | $13.70 |
| ATR | 0.0178 |
| Shares Float | 1.87B |
| Volatility | 0.04 |
Performance History
| Week | +0.00% |
| Month | -5.76% |
| Quarter | -9.92% |
| 6 Months | -30.67% |
| YTD | -28.29% |
| 10 Years | -28.29% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-11-02 | $12.25 | 0 |
| 2026-10-30 | $12.25 | 0 |
| 2026-10-29 | $12.25 | 0 |
| 2026-10-28 | $12.25 | 0 |
| 2026-10-27 | $12.25 | 0 |
| 2026-10-26 | $12.25 | 0 |
| 2026-10-23 | $12.25 | 0 |
| 2026-10-22 | $12.25 | 0 |
| 2026-10-21 | $12.25 | 0 |
| 2026-10-20 | $12.25 | 0 |
| 2026-10-19 | $12.25 | 0 |
| 2026-10-16 | $12.25 | 0 |
| 2026-10-15 | $12.25 | 100 |
| 2026-10-14 | $12.50 | 0 |
| 2026-10-13 | $12.50 | 0 |
| 2026-10-12 | $12.50 | 0 |
| 2026-10-09 | $12.50 | 0 |
| 2026-10-08 | $12.50 | 0 |
| 2026-10-07 | $12.50 | 0 |
| 2026-10-06 | $12.50 | 0 |
| 2026-10-05 | $12.50 | 211 |
About Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
đ° Latest News
No news articles available at the moment. Check back later for updates on JHPCY.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $639,338,746 | $563,942,931 | $516,618,224 | $510,960,165 |
| Cost Of Revenue | $639,338,746 | $563,942,931 | $516,618,224 | $510,960,165 |
| Total Revenue | $4,635,229,582 | $4,101,089,623 | $3,344,195,183 | $3,117,849,644 |
| Operating Revenue | $4,635,229,582 | $4,101,089,623 | $3,344,195,183 | $3,117,849,644 |
| Expenses | ||||
| Interest Expense | $2,102,832 | $814,624 | $865,187 | $951,368 |
| Total Expenses | $3,375,442,117 | $3,104,103,743 | $2,666,303,673 | $2,627,687,315 |
| Other Non Operating Income Expenses | $-41,381,846 | $-47,033,429 | $-35,581,171 | $-21,024,936 |
| Net Non Operating Interest Income Expense | $112,889,218 | $87,456,543 | $68,949,125 | $55,348,090 |
| Total Other Finance Cost | $104,917 | $137,952 | $110,130 | $161,886 |
| Interest Expense Non Operating | $2,102,832 | $814,624 | $865,187 | $951,368 |
| Operating Expense | $2,736,103,371 | $2,540,160,812 | $2,149,685,449 | $2,116,727,150 |
| Other Operating Expenses | $38,629,673 | $37,792,394 | $32,131,708 | $27,901,100 |
| Selling And Marketing Expense | $816,252,763 | $814,078,991 | $738,764,048 | $652,867,319 |
| General And Administrative Expense | $262,037,159 | $244,091,880 | $209,308,647 | $257,052,403 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,130,040,123 | $928,605,741 | $630,513,639 | $572,471,688 |
| Net Interest Income | $112,889,218 | $87,456,543 | $68,949,125 | $55,348,090 |
| Interest Income | $115,096,968 | $88,409,119 | $69,924,442 | $56,461,344 |
| Normalized Income | $1,121,360,346 | $914,294,494 | $649,998,252 | $585,291,167 |
| Net Income From Continuing And Discontinued Operation | $1,130,040,123 | $928,605,741 | $630,513,639 | $572,471,688 |
| Total Operating Income As Reported | $1,317,467,476 | $1,097,737,588 | $719,537,042 | $602,599,757 |
| Net Income Common Stockholders | $1,130,040,123 | $928,605,741 | $630,513,639 | $572,471,688 |
| Net Income | $1,130,040,123 | $928,605,741 | $630,513,639 | $572,471,688 |
| Net Income Including Noncontrolling Interests | $1,130,911,708 | $928,674,272 | $626,906,325 | $559,101,597 |
| Net Income Continuous Operations | $1,130,911,708 | $928,674,272 | $626,906,325 | $559,101,597 |
| Pretax Income | $1,276,085,630 | $1,050,704,160 | $683,955,871 | $581,574,821 |
| Special Income Charges | $-15,642,918 | $272,149 | $-12,720,306 | $-24,546,058 |
| Interest Income Non Operating | $115,096,968 | $88,409,119 | $69,924,442 | $56,461,344 |
| Operating Income | $1,259,787,465 | $996,985,880 | $677,891,510 | $490,162,329 |
| Depreciation And Amortization In Income Statement | $14,575,788 | $11,495,825 | $16,610,723 | $5,551,842 |
| Depreciation Income Statement | $14,575,788 | $11,495,825 | $16,610,723 | $5,551,842 |
| Gross Profit | $3,995,890,836 | $3,537,146,691 | $2,827,576,959 | $2,606,889,479 |
| Per Share | ||||
| Diluted EPS | $0.17 | $0.15 | $0.10 | $0.09 |
| Basic EPS | $0.17 | $0.15 | $0.10 | $0.09 |
| Other | ||||
| Tax Effect Of Unusual Items | $1,114,214 | $1,880,530 | $-1,773,133 | $-515,282 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,392,193,522 | $1,149,052,711 | $809,341,791 | $680,549,976 |
| Total Unusual Items | $9,793,991 | $16,191,778 | $-21,257,746 | $-13,334,761 |
| Total Unusual Items Excluding Goodwill | $9,793,991 | $16,191,778 | $-21,257,746 | $-13,334,761 |
| Reconciled Depreciation | $123,799,051 | $113,725,705 | $103,262,988 | $84,689,026 |
| EBITDA (Bullshit earnings) | $1,401,987,513 | $1,165,244,488 | $788,084,045 | $667,215,215 |
| EBIT | $1,278,188,462 | $1,051,518,784 | $684,821,058 | $582,526,190 |
| Diluted Average Shares | $957,661,121 | $928,605,741 | $927,225,939 | $938,478,177 |
| Basic Average Shares | $949,613,549 | $928,605,741 | $927,225,939 | $938,478,177 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Minority Interests | $-871,585 | $-68,531 | $3,607,314 | $13,370,091 |
| Tax Provision | $145,173,922 | $122,029,888 | $57,049,546 | $22,473,224 |
| Other Special Charges | $-593,979 | $-791,054 | $-463,460 | $-802,161 |
| Write Off | $3,499,813 | $-4,249,526 | $-2,528,613 | $3,851,931 |
| Impairment Of Capital Assets | $12,737,084 | $4,768,431 | $15,712,379 | $21,496,288 |
| Research And Development | $1,020,143,821 | $964,713,502 | $725,982,545 | $716,114,811 |
| Selling General And Administration | $1,078,289,922 | $1,058,170,871 | $948,072,695 | $909,919,722 |
Fetched: 2026-04-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,977,737,981 | $5,933,730,320 | $5,435,391,217 | $5,220,427,581 |
| Total Assets | $10,238,919,584 | $7,347,281,556 | $6,416,534,506 | $6,209,369,663 |
| Total Non Current Assets | $2,693,105,392 | $2,171,947,480 | $1,831,416,303 | $1,676,044,033 |
| Other Non Current Assets | $89,641,716 | $70,212,165 | $56,171,560 | $64,854,863 |
| Non Current Deferred Assets | $31,100,372 | $40,248,369 | $49,242,558 | $54,389,061 |
| Non Current Deferred Taxes Assets | $114,447,718 | $55,274,210 | $46,976,883 | $35,009,955 |
| Investmentin Financial Assets | $215,805,993 | $156,133,894 | $110,847,675 | $108,403,179 |
| Goodwill And Other Intangible Assets | $1,001,564,811 | $737,117,127 | $494,792,589 | $322,541,862 |
| Other Intangible Assets | $1,001,564,811 | $737,117,127 | $494,792,589 | $322,541,862 |
| Current Assets | $7,545,814,192 | $5,175,334,076 | $4,585,118,202 | $4,533,325,630 |
| Other Current Assets | $80,381,501 | $63,812,263 | $48,954,312 | $95,822,554 |
| Prepaid Assets | $154,836,579 | $168,125,715 | $178,947,052 | $154,577,982 |
| Inventory | $421,825,767 | $354,224,024 | $339,116,021 | $359,126,977 |
| Other Receivables | $115,921,947 | $192,126,064 | $202,040,906 | $441,439,300 |
| Accounts Receivable | $754,218,695 | $720,265,046 | $761,242,954 | $863,372,849 |
| Cash Cash Equivalents And Short Term Investments | $6,018,629,702 | $3,676,780,964 | $3,054,816,957 | $2,618,985,968 |
| Cash And Cash Equivalents | $6,001,946,502 | $3,636,722,831 | $3,040,301,432 | $2,214,440,932 |
| Cash Equivalents | $14,805,080 | $2,368,468 | $954 | $48,992 |
| Cash Financial | $5,987,141,422 | $3,634,354,364 | $3,040,300,478 | $2,214,391,940 |
| Allowance For Doubtful Accounts Receivable | - | $-7,855,958 | $-12,057,230 | $-14,367,915 |
| Gross Accounts Receivable | - | $728,121,005 | $773,300,184 | $877,740,764 |
| Debt | ||||
| Total Debt | $10,878,713 | $16,144,037 | $11,016,954 | $199,276,652 |
| Long Term Debt And Capital Lease Obligation | $6,346,616 | $10,117,112 | $11,016,954 | $14,487,832 |
| Current Debt And Capital Lease Obligation | $4,532,098 | $6,026,925 | - | $184,788,820 |
| Current Debt | - | - | - | $184,788,820 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,182,714,999 | $592,844,726 | $403,215,292 | $580,032,430 |
| Total Non Current Liabilities Net Minority Interest | $249,315,631 | $60,348,322 | $28,981,574 | $46,711,857 |
| Other Non Current Liabilities | $170,663,981 | - | - | - |
| Non Current Deferred Taxes Liabilities | $17,140,716 | $17,162,572 | $12,256,573 | $14,720,324 |
| Current Liabilities | $933,399,368 | $532,496,404 | $374,233,718 | $533,320,573 |
| Other Current Liabilities | $519,435 | $515,351 | $1,793,433 | $1,667,389 |
| Payables | $648,066,871 | $502,536,708 | $343,410,506 | $319,448,816 |
| Other Payable | $197,264,649 | $151,663,547 | $89,985,172 | $42,952,211 |
| Total Tax Payable | $118,070,929 | $62,575,151 | $32,089,530 | $17,465,786 |
| Accounts Payable | $332,731,293 | $288,298,011 | $221,335,805 | $259,030,818 |
| Equity | ||||
| Common Stock Equity | $8,979,302,792 | $6,670,847,447 | $5,930,183,806 | $5,542,969,443 |
| Total Equity Gross Minority Interest | $9,056,204,586 | $6,754,436,830 | $6,013,319,214 | $5,629,337,234 |
| Stockholders Equity | $8,979,302,792 | $6,670,847,447 | $5,930,183,806 | $5,542,969,443 |
| Retained Earnings | $5,887,327,214 | $4,962,927,577 | $4,220,990,112 | $3,739,936,924 |
| Long Term Equity Investment | $81,683,104 | $97,652,858 | $101,849,532 | $112,528,616 |
| Other | ||||
| Ordinary Shares Number | $972,668,765 | $934,830,408 | $934,830,408 | $934,830,408 |
| Share Issued | $972,668,765 | $934,830,408 | $934,830,408 | $934,830,408 |
| Tangible Book Value | $7,977,737,981 | $5,933,730,320 | $5,435,391,217 | $5,220,427,581 |
| Invested Capital | $8,979,302,792 | $6,670,847,447 | $5,930,183,806 | $5,727,758,263 |
| Working Capital | $6,612,414,824 | $4,642,837,672 | $4,210,884,485 | $4,000,005,058 |
| Capital Lease Obligations | $6,346,616 | $10,117,112 | $11,016,954 | $14,487,832 |
| Total Capitalization | $8,979,302,792 | $6,670,847,447 | $5,930,183,806 | $5,542,969,443 |
| Minority Interest | $76,901,794 | $83,589,383 | $83,135,408 | $86,367,791 |
| Treasury Stock | $282,702,307 | $180,052,529 | $160,008,612 | $58,330,210 |
| Additional Paid In Capital | $1,847,625,416 | $436,151,194 | $437,911,615 | $437,911,615 |
| Capital Stock | $972,668,765 | $934,830,408 | $934,830,408 | $934,830,408 |
| Common Stock | $972,668,765 | $934,830,408 | $934,830,408 | $934,830,408 |
| Non Current Deferred Revenue | $55,164,318 | $33,068,638 | $5,708,047 | $17,503,700 |
| Long Term Capital Lease Obligation | $6,346,616 | $10,117,112 | $11,016,954 | $14,487,832 |
| Available For Sale Securities | $215,805,993 | $156,133,894 | $110,847,675 | $108,403,179 |
| Net PPE | $1,158,861,679 | $1,015,308,858 | $971,535,506 | $978,316,498 |
| Accumulated Depreciation | $-818,518,335 | $-724,878,251 | $-640,611,461 | $-562,972,707 |
| Gross PPE | $1,977,380,013 | $1,740,187,109 | $1,612,146,967 | $1,541,289,205 |
| Construction In Progress | $294,030,398 | $247,303,655 | $161,348,640 | $174,860,925 |
| Other Properties | $50,327,176 | $52,709,746 | $45,270,541 | $45,141,939 |
| Machinery Furniture Equipment | $916,053,838 | $857,709,587 | $840,764,754 | $802,403,029 |
| Properties | $716,968,601 | $582,464,121 | $564,763,032 | $518,883,312 |
| Inventories Adjustments Allowances | $0 | $0 | $0 | $0 |
| Other Inventories | $1,397,843 | $1,349,300 | $1,216,564 | $3,945,395 |
| Finished Goods | $184,435,806 | $184,728,277 | $167,962,147 | $168,460,866 |
| Work In Process | $91,417,898 | $63,871,794 | $59,475,330 | $59,002,177 |
| Raw Materials | $144,574,221 | $104,274,652 | $110,461,981 | $127,718,539 |
| Other Short Term Investments | $16,683,200 | $40,058,133 | $14,515,525 | $404,545,036 |
Fetched: 2026-04-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,212,461,249 | $799,207,986 | $902,717,486 | $-106,527,702 |
| Operating Activities | ||||
| Operating Cash Flow | $1,646,522,868 | $1,087,790,058 | $1,120,164,288 | $185,422,077 |
| Cash Flowsfromusedin Operating Activities Direct | $1,646,522,868 | $1,087,790,058 | $1,120,164,288 | $185,422,077 |
| Other Cash Paymentsfrom Operating Activities | $-1,715,597,402 | $-1,639,928,791 | $-1,355,458,045 | $-1,332,256,425 |
| Classesof Cash Receiptsfrom Operating Activities | $5,104,878,554 | $4,172,059,390 | $3,720,775,034 | $2,827,612,782 |
| Other Cash Receiptsfrom Operating Activities | $180,002,589 | $193,746,903 | $189,857,450 | $106,590,576 |
| Investing Activities | ||||
| Capital Expenditure | $-434,061,620 | $-288,582,072 | $-217,446,802 | $-291,949,779 |
| Investing Cash Flow | $-401,615,306 | $-280,197,797 | $179,127,908 | $57,196,150 |
| Financing Activities | ||||
| Financing Cash Flow | $1,140,394,119 | $-227,235,960 | $-460,809,574 | $-46,715,156 |
| Net Other Financing Charges | $1,329,248,124 | $-40,418,212 | $-126,265,684 | $-82,539,889 |
| Cash Dividends Paid | $-188,205,181 | $-186,817,748 | $-149,893,334 | $-148,825,822 |
| Other | ||||
| Repayment Of Debt | $-219,822,090 | $-117,225,168 | $-187,742,720 | - |
| Issuance Of Debt | $219,173,266 | $117,225,168 | $3,092,164 | $184,650,556 |
| End Cash Position | $5,884,718,346 | $3,552,193,391 | $2,970,752,555 | $2,130,433,226 |
| Beginning Cash Position | $3,552,193,391 | $2,970,752,555 | $2,130,433,226 | $1,922,733,422 |
| Effect Of Exchange Rate Changes | $-52,776,727 | $1,084,536 | $1,836,707 | $11,796,733 |
| Changes In Cash | $2,385,301,681 | $580,356,300 | $838,482,622 | $195,903,071 |
| Net Issuance Payments Of Debt | $-648,824 | $0 | $-184,650,556 | $184,650,556 |
| Net Long Term Debt Issuance | $-648,824 | $0 | $-184,650,556 | $184,650,556 |
| Long Term Debt Payments | $-219,822,090 | $-117,225,168 | $-187,742,720 | - |
| Long Term Debt Issuance | $219,173,266 | $117,225,168 | $3,092,164 | $184,650,556 |
| Net Investment Purchase And Sale | $29,674,829 | $5,174,617 | $393,616,798 | $340,901,370 |
| Sale Of Investment | $29,674,829 | $96,427,223 | $396,120,656 | $1,431,606,884 |
| Net PPE Purchase And Sale | $-431,290,134 | $-285,372,414 | $-214,488,891 | $-288,987,606 |
| Sale Of PPE | $2,771,485 | $3,209,657 | $2,957,911 | $2,962,172 |
| Purchase Of PPE | $-434,061,620 | $-288,582,072 | $-217,446,802 | $-291,949,779 |
| Change In Working Capital | $315,732,839 | $20,067,861 | $349,062,992 | $-420,651,676 |
| Change In Other Current Assets | $-59,195,364 | $-3,391,327 | $-14,430,680 | $-3,239,830 |
| Change In Payable | $605,948,401 | $98,393,634 | $46,209,902 | $-74,893,089 |
| Change In Inventory | $-70,231,322 | $-19,876,433 | $18,920,197 | $-7,719,589 |
| Change In Receivables | $-160,788,877 | $-55,058,013 | $298,363,573 | $-334,799,168 |
| Other Non Cash Items | $69,197,715 | $13,621,357 | $13,952,170 | $10,661,741 |
| Depreciation And Amortization | $123,799,051 | $113,725,705 | $103,262,988 | $84,689,026 |
| Amortization Cash Flow | $16,791,746 | $9,857,406 | $5,582,981 | $3,294,673 |
| Depreciation | $107,007,305 | $103,868,299 | $97,680,006 | $81,394,352 |
| Gain Loss On Investment Securities | $-17,013,227 | $-19,417,480 | $5,220,154 | $-78,232,931 |
| Gain Loss On Sale Of PPE | $-111,859 | $-66,516 | $447,059 | $-620,252 |
| Net Income From Continuing Operations | $1,130,911,708 | $928,674,272 | $626,906,325 | $559,101,597 |
| Taxes Refund Paid Direct | $-408,449,336 | $-335,617,105 | $-229,758,927 | $-239,035,560 |
| Classesof Cash Payments | $-3,049,906,349 | $-2,748,652,227 | $-2,370,851,819 | $-2,403,155,145 |
| Paymentson Behalfof Employees | $-1,026,563,421 | $-903,241,008 | $-842,962,435 | $-913,605,480 |
| Paymentsto Suppliersfor Goodsand Services | $-307,745,526 | $-205,482,428 | $-172,431,339 | $-157,293,239 |
| Receiptsfrom Customers | $4,924,875,965 | $3,978,312,487 | $3,530,917,584 | $2,721,022,207 |
| Purchase Of Investment | - | $-91,252,606 | $-2,503,857 | $-1,090,705,513 |
| Net Business Purchase And Sale | - | - | - | $5,282,385 |
| Sale Of Business | - | - | - | $5,282,385 |
Fetched: 2026-04-22